ECT and Neuroleptic Malignant Syndrome (NMS): A Critical Contraindication
Electroconvulsive therapy (ECT) is contraindicated in patients with active neuroleptic malignant syndrome (NMS).
Why?
- NMS is a life-threatening reaction to antipsychotics: high fever, severe muscle rigidity, autonomic instability, altered consciousness.
- ECT induces a controlled seizure, which exacerbates NMS pathophysiology—increasing metabolic demand, muscle breakdown (rhabdomyolysis), and autonomic dysregulation.
- Combined, they can precipitate fatal complications: hyperthermia, cardiac arrest, renal failure from myoglobinuria.
Clinical Protocol
- Recognize NMS: stop antipsychotic, aggressive supportive care (cooling, hydration, dantrolene/bromocriptine per protocol).
- Defer ECT until NMS fully resolved and patient stabilized.
- If ECT is later needed, use modified protocols with close monitoring.
This is a well-established safety principle in psychiatry and neurology.
Neurological Disorders - Related Articles
- Cerebral Palsy Therapy: Effective Medical & Physical Treatment Options
- Guillain-Barré Syndrome and Seizures: Understanding the Connection
- Understanding and Testing Tilting Reflexes in Infants
- Complex Regional Pain Syndrome (CRPS): Understanding and Managing RSD
- Understanding Parkinson's Disease: Symptoms, Causes & Management
- Nephrotic Syndrome: Symptoms, Pathophysiology, and Management
- Vertigo: Causes, Symptoms & Effective Remedies